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EVIDENCE-BASED ANSWER
A
 Childhood alopecia areata: 
What treatment works best? 
 it’s unclear; there are no validat-
 ed eff ective treatments for alope-
cia areata (AA). Topical immunotherapy 
(squaric acid dibutylester [SADBE] and 
diphenylcyclopropenone [DPCP]) in-
duces the most signifi cant short-term 
hair regrowth in children with severe AA 
(strength of recommendation [SOR]: C, 4 
small individual cohort studies and 1 mod-
erately sized retrospective case review). 
Intralesional steroids can induce hair re-
growth greater than 50% in children with 
limited AA (SOR: C, 1 retrospective cohort 
study). 
Other commonly used treatments—topi-
cal and oral corticosteroids, topical cy-
closporine, photodynamic therapy, and 
topical minoxidil—have no benefi t over 
placebo (SOR: A, 14 randomized controlled 
trials [RCTs] and 3 within-patient studies).
Evidence summary
AA is a common infl ammatory condition 
that causes hair loss and subsequent so-
cial consequences. Spontaneous remission 
occurs in 34% to 50% of patients within 1 
year.1 Many trials of commonly used AA 
treatments have identifi ed no signifi cant 
patient benefi ts. A 2008 Cochrane review 
that examined 17 studies (14 RCTs and 
3   within-patient studies)  of AA interventions 
in 540 participants found no clinically sig-
nifi cant hair regrowth (>50%) when patients 
were treated with topical corticosteroids, cy-
closporine, minoxidil, photodynamic thera-
py, or oral corticosteroids.2 
Documenting patient outcomes is prob-
lematic because of spontaneous resolution 
and frequent relapses.2 Moreover, few quality-
controlled trials have studied children, and no 
long-term, randomized outcome trials of AA 
treatments exist. 
Intralesional steroids and SADBE 
show results 
In a moderately sized retrospective cohort 
study in Singapore (392 patients <16 years), 
57% of patients experienced more than 50% 
improvement after 12 weeks of intralesional 
steroids for limited AA, and 75% showed simi-
lar improvement after 24 weeks. Of 43 children 
treated with anthralin, only 10 with limited AA 
showed more than 50% clinical improvement 
within 6 months.3 Fifty-four patients with ex-
tensive AA received SADBE; 74% experienced 
greater than 50% hair regrowth at 6 months.3
SADBE effects aren’t long-lived
A 1996 individual cohort study of 33 children 
(6-14 years of age) with extensive AA who were 
treated with SADBE once a week for a year 
showed a complete regrowth rate of 30.3%. 
Only 9% of the children maintained total or 
partial regrowth during long-term follow-up 
(mean 6 years), however.4 
In another individual cohort study, 28 pe-
diatric patients with extensive AA had mixed 
results with 2% SADBE used once a week for 
a year.5 Nine patients (32.1%) showed total 
or acceptable hair growth; 6 (21.4%) had dif-
fuse regrowth but thinner than normal hair. 
Eighty-seven percent of patients relapsed 
within 6 months of discontinuing therapy.5
Studies of DPCP are too small 
A 1996 small individual cohort investigation 
recorded a 40% response rate (90%-100% re-
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Intralesional 
steroids can 
result in hair 
regrowth >50% 
in children 
with limited 
alopecia areata.
References
growth) to DPCP in 10 pediatric patients with 
extensive AA who were treated for an average 
of 8.6 months. Th e same study found cosmeti-
cally acceptable growth in 27% of patients 
(4 of 15 patients 4-15 years of age) treated for 
an average of 9.6 months.6
A small individual study of DPCP report-
ed complete regrowth in 4 of 12 (33%) chil-
dren with extensive AA; growth persisted at 
6 months in 3 of the 4 responders.7 Another 
cohort study reported a 50% response rate 
(>80% regrowth) using DPCP in 10 patients 
(11-14 years of age) with extensive disease.8
Use SADBE and DPCP with caution
SADBE and DPCP are unlicensed treatments 
that can cause occipital and cervical lymph-
adenopathy, severe dermatitis (minimized 
by careful titration), urticaria, and hypo- or 
hyperpigmentation disorders (especially in 
racially pigmented patients). Th ese agents 
shouldn’t be used during pregnancy and 
should be applied using gloves and aprons to 
avoid allergic contact dermatitis. 
In light of these cautions, and handling and 
storage limitations, SADBE and DPCP should 
be reserved for patients with extensive disease 
(after obtaining signed informed consent). 
Patients should avoid ultraviolet light for 24 to 
48 hours after application to avoid degrada-
tion of the medication.
Recommendations
Th e National Alopecia Areata Foundation and 
the American Academy of Dermatology rec-
ommend corticosteroids, topical minoxidil, 
and anthralin to treat AA.9,10
Th e British Association of Dermatolo-
gists’ guidelines for managing AA advise us-
ing intralesional corticosteroids for limited AA 
and contact immunotherapy for more exten-
sive disease.1 Th ey also note that intralesional 
corticosteroids are poorly tolerated and clini-
cians are reluctant to use contact immuno-
therapy in children.               JFP
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